Quetiapine
- Generic Name
- Quetiapine
- Brand Names
- Seroquel
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25N3O2S
- CAS Number
- 111974-69-7
- Unique Ingredient Identifier
- BGL0JSY5SI
- Background
Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivi...
- Indication
Quetiapine is used in the symptomatic treatment of schizophrenia. In addition, it may be used for the management of acute manic or mixed episodes in patients with bipolar I disorder, as a monotherapy or combined with other drugs. It may be used to manage depressive episodes in bipolar disorder. In addition to the above indications, quetiapine is used in comb...
- Associated Conditions
- Bipolar 1 Disorder, Depressive Episodes, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode
- Associated Therapies
- -
Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis
- Conditions
- Interventions
- First Posted Date
- 2020-05-04
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 358
- Registration Number
- NCT04373317
- Locations
- 🇺🇸
Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States
🇺🇸Southern Arizona VA Health Care System, Tucson, AZ, Tucson, Arizona, United States
🇺🇸South Texas Health Care System, San Antonio, TX, San Antonio, Texas, United States
Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine
- Conditions
- Interventions
- First Posted Date
- 2019-11-15
- Last Posted Date
- 2021-10-14
- Lead Sponsor
- ACADIA Pharmaceuticals Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT04164758
- Locations
- 🇺🇸
Movement Disorders Center of Arizona, Scottsdale, Arizona, United States
🇺🇸Tucson Neuroscience Research, Tucson, Arizona, United States
🇺🇸Galiz Research, Hialeah, Florida, United States
Quetiapine Treatment for Pediatric Delirium
- First Posted Date
- 2018-06-28
- Last Posted Date
- 2020-04-08
- Lead Sponsor
- Medical College of Wisconsin
- Registration Number
- NCT03572257
- Locations
- 🇺🇸
Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States
A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2020-07-16
- Target Recruit Count
- 44
- Registration Number
- NCT03568500
- Locations
- 🇬🇧
Clinical Trial Site, Southampton, United Kingdom
A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication
- First Posted Date
- 2018-06-15
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 233
- Registration Number
- NCT03557931
- Locations
- 🇺🇸
CNS Research Science, Inc., Jamaica, New York, United States
🇺🇸Synergy East, Lemon Grove, California, United States
🇺🇸Pacific Research Partners, LLC, Oakland, California, United States
Bariatric Surgery and Pharmacokinetics of Quetiapine
- Conditions
- First Posted Date
- 2018-02-28
- Last Posted Date
- 2023-03-27
- Lead Sponsor
- Norwegian University of Science and Technology
- Target Recruit Count
- 12
- Registration Number
- NCT03449472
- Locations
- 🇳🇴
St. Olavs University Hospital, Trondheim, Norway
A Survey on Quetiapine Extended-release Tablets in Patients With Depression in Bipolar Disorder
- First Posted Date
- 2018-01-19
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 369
- Registration Number
- NCT03403790
- Locations
- 🇯🇵
Site JP00005, Akita, Japan
🇯🇵Site JP00038, Ehime, Japan
🇯🇵Site JP00007, Fukushima, Japan
Bioequivalence Study of Two Extended Release Formulations Containing 50 mg of Quetiapine.
- First Posted Date
- 2017-10-23
- Last Posted Date
- 2017-10-23
- Lead Sponsor
- Laboratorio Elea Phoenix S.A.
- Target Recruit Count
- 24
- Registration Number
- NCT03317236
- Locations
- 🇦🇷
DominguezLab, Paraná, Entre Ríos, Argentina
Lithium Versus Quetiapine in Treatment Resistant Depression
- First Posted Date
- 2016-12-29
- Last Posted Date
- 2021-03-05
- Lead Sponsor
- King's College London
- Target Recruit Count
- 276
- Registration Number
- NCT03004521
- Locations
- 🇬🇧
Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom
Pharmacokinetics of Quetiapine Across Pregnancy and Postpartum
- First Posted Date
- 2016-12-01
- Last Posted Date
- 2022-09-27
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 4
- Registration Number
- NCT02978534
- Locations
- 🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.